Which longevity biotech startups have the most credible science?

The longevity biotech startups with the most credible science today are BioAge, Cambrian Bio and Rubedo if we prioritize evidence already generated in humans, while Life Biosciences, NewLimit and Junevity lead the more ambitious attempt to actually reset aging biology.

The ranking changes depending on what we mean by credible. A company can have an extraordinary theory of rejuvenation and still be years away from knowing whether its therapy works in people. Another company can generate excellent human pharmacology while targeting one fairly conventional pathway associated with aging. We should reward both, but we should not pretend the evidence is equally mature.

For this ranking, we give the most weight to evidence that survives several steps: the aging mechanism makes biological sense, manipulating it improves function rather than simply changing an aging biomarker, the effect survives animal testing, the drug hits its intended target in people and, ultimately, patients improve.

That last step remains rare. No longevity startup has shown that its treatment slows whole-body human aging or extends human lifespan. What has changed is that several companies are now testing aging-derived hypotheses in randomized human studies instead of asking us to extrapolate indefinitely from mice.

Company	Main approach	Evidence stage today	Our current view
BioAge Labs	NLRP3 and targets derived from human aging data	Two Phase 2 programs	Strongest current human evidence package
Cambrian Bio	AMPK activation and selective mTORC1 inhibition	ATX-304 moving into Phase 2	Strongest bridge from classic geroscience to human pharmacology
Rubedo Life Sciences	Targeting pathological senescent and stressed cells	Phase 1/2	Interesting early human efficacy signal, still small
Life Biosciences	Partial epigenetic reprogramming with OSK	Phase 1	Most important human test of cellular rejuvenation
Retro Biosciences	Autophagy, cell replacement and reprogramming	Phase 1	Serious clinical program with limited public human data
NewLimit	Epigenetic reprogramming with selected transcription factors	Late preclinical	One of the strongest preclinical engineering programs
Junevity	Transcriptional network resetting with siRNA	Preclinical	Unusually strong published mechanistic foundation
Altos Labs	Cellular rejuvenation and stress resilience	Mainly preclinical publicly	Exceptional research base, little public therapeutic evidence
Loyal	Longevity drugs for companion dogs	Pivotal veterinary development	Valuable direct test of mammalian lifespan intervention

Has longevity biotech finally moved beyond mouse experiments?

Yes. Longevity biotech has clearly moved into human testing now, although only a handful of companies have generated data strong enough to tell us whether their aging theories survive contact with real patients.

BioAge has already completed Phase 1 testing of its NLRP3 inhibitor BGE-102 and has two Phase 2 programs running. Cambrian's ATX-304 has completed a randomized Phase 1b study and is moving toward Phase 2. Rubedo has reported early clinical results with its GPX4-modulating drug RLS-1496. Retro's autophagy drug RTR242 is in Phase 1. Life Biosciences has started treating patients with ER-100, the first partial epigenetic reprogramming therapy to reach human testing.

That is a substantial change from the earlier longevity industry, where impressive claims often rested on extended lifespan in mice, worms or flies.

The important caveat is that these human studies generally measure inflammation, metabolism, skin lesions, eye disease or another specific condition. They are tests of therapies derived from aging biology, not direct trials showing that humans are aging more slowly.

Still, we finally have experiments capable of killing bad ideas. That alone makes today's longevity biotech much easier to judge than it was a few years ago.

Does BioAge currently have the strongest human science in longevity biotech?

BioAge currently has the strongest overall human evidence among companies explicitly built around aging biology, although BGE-102 still has to prove that dramatic target engagement turns into meaningful clinical benefit.

BGE-102 inhibits NLRP3, a central component of an inflammatory pathway increasingly linked with cardiovascular, metabolic and retinal disease. In BioAge's Phase 1 study, the 60 mg and 120 mg daily doses produced median reductions of about 86% in high-sensitivity C-reactive protein among participants with obesity and elevated inflammation. The company also reported up to 98% suppression of IL-1β in an ex-vivo whole-blood assay.

Those are very large pharmacodynamic effects. More importantly, BioAge has moved quickly from showing that BGE-102 hits the pathway into testing whether the biology holds up in actual disease.

Its QUELL-CV Phase 2 study enrolled roughly 160 adults with obesity, elevated inflammation and cardiovascular risk. Enrollment has now been completed. Participants receive placebo or one of three BGE-102 doses for 12 weeks, with change in hsCRP as the primary endpoint.

BioAge has also started QUELL-DME, a separate randomized Phase 2 trial involving about 180 people with diabetic macular edema. That study is more demanding scientifically because its primary endpoint is change in best-corrected visual acuity rather than another inflammatory biomarker.

So BGE-102 is now being challenged in two different human settings: systemic cardiovascular inflammation and retinal disease. Few longevity companies currently have that breadth of clinical testing around one aging-related mechanism.

The limitation is obvious. If BGE-102 lowers inflammation and treats diabetic eye disease, BioAge will have developed a useful anti-inflammatory medicine. We would still need much more evidence before saying it slows human aging itself.

If you want more recent data on this point, please see our latest longevity biotech market report.

Did BioAge's failed azelaprag program expose a weakness in its aging platform?

BioAge's azelaprag failure damaged the company's track record, and it is a useful reminder that attractive aging biology can collapse once enough people receive the drug.

Azelaprag was an apelin-receptor agonist that BioAge hoped could mimic some physiological effects associated with exercise. The program reached the Phase 2 STRIDES obesity trial before development was stopped after liver transaminase elevations appeared in 11 of 204 enrolled participants receiving azelaprag.

The drug had looked promising enough to reach a reasonably sized clinical experiment. Human safety killed it anyway.

That history makes us more cautious about treating BioAge's discovery platform as validated. One lead program has already failed in translation.

BGE-102 still deserves to be judged on its own data. Its Phase 1 safety profile was substantially cleaner, target engagement was unusually strong and BioAge has already pushed it into two randomized Phase 2 programs. The upcoming QUELL-CV readout will tell us much more about BioAge than another preclinical aging study ever could.

Is Cambrian Bio now one of the strongest longevity biotechs scientifically?

Yes. Cambrian Bio now belongs close to the top of the scientific ranking because ATX-304 has produced measurable metabolic effects in people and is advancing toward larger Phase 2 studies.

ATX-304 activates AMPK and mitochondrial metabolism. AMPK is one of the better-established energy-sensing systems in aging biology: its activity is tied to exercise, nutrient availability, glucose handling, fat metabolism and several pathways that repeatedly show up in experimental geroscience.

Cambrian tested ATX-304 in 23 adults with obesity and prediabetes in a randomized Phase 1b study. According to results presented at the American Diabetes Association's scientific meeting, treatment significantly improved liver fat, visceral fat, triglycerides and adiponectin. Resting metabolic rate increased by as much as 33% from baseline.

A 23-person study cannot establish that the drug will work commercially or clinically at scale. Still, several physiological measurements moved together in the expected direction rather than one convenient biomarker moving on its own.

Cambrian now lists ATX-304 as entering Phase 2, with REWIRE-1 and REWIRE-2 planned to examine its effects on metabolism, exercise-like physiology and muscle-sparing weight loss.

The company also has a second aging program that gives the portfolio more depth. Its TORnado platform is developing highly selective mTORC1 inhibitors, and ARPA-H has committed up to $30.8 million to advance a program designed to improve intrinsic capacity in older adults.

mTOR inhibition sits among the most reproducible interventions in experimental geroscience, while AMPK is another central nutrient-sensing pathway. Cambrian is testing two mechanisms with decades of biology behind them rather than relying on a newly discovered aging marker.

If you want more recent data on this point, please see our latest longevity biotech market report.

Can Rubedo's senolytic drug actually work in humans?

Rubedo has produced one of the better early human results in the senescence field, but the study is still small enough that we should treat the 46% lesion reduction as a promising clue rather than proof that its platform works.

RLS-1496 targets GPX4 biology and is designed to affect pathological senescent and stressed cells. Rubedo's approach is more selective than the early idea that longevity drugs should simply kill any cell carrying a broad senescence signature.

In an early Phase 1b/2a study of actinic keratosis, roughly two dozen participants applied topical RLS-1496 to one forearm. Rubedo reported a 46% reduction in precancerous lesions after four weeks, compared with roughly 11% on untreated control arms, while irritation was limited.

Actinic keratosis is a visible human pathology, so this is more useful than another molecular senescence marker moving in the right direction.

There are reasons to remain cautious. The trial was small and open-label, while the comparator was untreated skin rather than a placebo cream. We also do not yet know how tightly the clinical improvement depends on the proposed senescence mechanism.

Rubedo has nevertheless kept expanding the test. The company has reported early results in inflammatory skin conditions and recently announced a study of RLS-1496 in hair loss after reporting ex-vivo human hair-follicle growth.

The sequence is more interesting than any single announcement. Rubedo is repeatedly testing the same drug across conditions where pathological aged cells may play a role. If those effects continue to appear in controlled studies, the company could become the clearest human validation yet for a targeted senescence strategy.

Has Life Biosciences made partial epigenetic reprogramming scientifically credible?

Life Biosciences has turned partial epigenetic reprogramming from a spectacular animal experiment into a real human clinical test, making ER-100 the most important high-risk longevity program currently in patients.

The scientific foundation comes from work showing that controlled expression of OCT4, SOX2 and KLF4 could restore more youthful molecular patterns in retinal ganglion cells while improving axon regeneration and visual function in old or injured mice.

Visual recovery was crucial. A treatment that merely changed a methylation clock would have been far less convincing because reprogramming directly alters the epigenetic state used by many aging clocks.

Life Biosciences has now packaged the same broad idea into ER-100, an AAV2-based gene therapy that delivers controlled OSK expression to retinal cells. The first patient in its Phase 1 trial was dosed in 2026, and the study is enrolling people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy.

The eye is a particularly smart first target. Treatment can be delivered locally, which limits whole-body exposure to powerful reprogramming factors, and investigators can measure actual visual function rather than rely entirely on molecular surrogates.

Life Biosciences has also announced that the first interim human ER-100 data will be presented at Eyecelerator 2026 on October 8. That readout could change this ranking quickly.

For now, we know that controlled partial reprogramming can restore meaningful function in animal models and that the therapy can be manufactured and administered to humans. We still do not know whether an old human neuron can be rejuvenated enough to improve vision safely.

If you want more recent data on this point, please see our latest longevity biotech market report.

How strong is NewLimit's reprogramming science before human trials?

NewLimit has one of the strongest preclinical reprogramming programs today because it increasingly measures whether old cells recover useful functions instead of selecting candidates merely because the cells look molecularly younger.

NewLimit searches through combinations of transcription factors and measures their effect using single-cell experiments, computational models and functional assays. Its most advanced program targets aged hepatocytes in the liver.

The company says its lead candidate restores resilience and regenerative capacity in old liver cells and improves metabolic responses in aged animals. In one model, old animals normally show a much stronger sedative response after alcohol exposure than young animals; animals treated with NewLimit's candidate behaved more like younger animals. NewLimit has also reported that some protective effects persist after the drug itself has cleared.

The platform is becoming broader as well. In its latest detailed technical update, NewLimit reported four additional leads that restore function in aged hepatocytes and five payloads that restore regenerative function in old endothelial cells. It also reported scaling manufacturing of its lead medicine by roughly 100-fold.

Those numbers are company-generated, so we should discount them compared with independently reproduced or clinical evidence. But there is a useful pattern underneath them. NewLimit has progressed from finding molecularly younger cells, to demonstrating functional recovery, to testing animals, to scaling a specific therapeutic candidate for the clinic.

The company now says its first reprogramming medicine is headed for human trials in 2027.

That is where NewLimit will face a much tougher standard. For now, we would rank its science among the best in preclinical longevity biotech while keeping it clearly below companies that already have human pharmacology.

Does Junevity have better science than its low profile suggests?

Yes. Junevity is one of the more scientifically interesting longevity startups because its core approach grew out of peer-reviewed experiments that identified specific regulators capable of reversing several aging-related cellular problems.

The founding work used Perturb-seq to test hundreds of transcription-factor perturbations in aging human fibroblasts. Researchers identified regulators including E2F3, EZH2, STAT3 and ZFX whose manipulation could reverse multiple aging-associated phenotypes.

The useful part was the breadth of those effects. The researchers measured changes in proliferation, mitochondrial function, proteostasis and cellular senescence instead of relying on one age score.

The work also moved into animals. Increasing EZH2 expression in old mouse livers shifted gene-expression patterns toward younger states while reducing fibrosis and fat accumulation and improving glucose tolerance.

Junevity is trying to turn that discovery logic into siRNA drugs that suppress transcriptional programs associated with age-related cellular dysfunction. The company has recently broadened its work through a target-discovery collaboration with Eli Lilly's ExploR&D unit in Parkinson's disease and another partnership with Amorepacific focused on skin rejuvenation.

Those partnerships do not validate the drugs, but they show that Junevity's RESET platform is being applied beyond its founding experiments.

Human translation remains the missing piece. Junevity currently deserves more scientific credit than its visibility might suggest, while its place in the ranking will stay below clinical-stage companies until a candidate reaches patients.

Is Retro Biosciences scientifically credible or mostly a very expensive bet?

Retro Biosciences is scientifically credible and has moved faster toward the clinic than its secretive image suggests, but the lack of detailed public human data keeps us from ranking it alongside BioAge or Cambrian today.

Retro is pursuing several approaches to age-related decline, including autophagy enhancement, cell replacement and partial reprogramming. Its most advanced drug, RTR242, is designed to increase autophagic flux and is being developed initially for Alzheimer's disease.

Autophagy has a serious scientific foundation. Cells rely on it to clear damaged proteins and organelles, the process becomes less efficient with age, and many of the best-known longevity pathways interact with this cellular recycling machinery.

Retro says RTR242 moved from indication selection to first-in-human dosing in only 15 months. The company now lists the program in Phase 1 and recently raised new financing at a $1.8 billion pre-money valuation to advance its broader pipeline.

The clinical speed is impressive. The evidence available to outsiders is thinner.

We still have little public information about RTR242's human target engagement, dose response or early efficacy. That makes Retro difficult to compare with BioAge's inflammatory data, Cambrian's metabolic measurements or Rubedo's skin-lesion results.

Retro could easily move up this ranking once it releases more data. At the moment, we are partly judging a credible mechanism and a real clinical program rather than a rich clinical dataset.

Should Altos Labs rank first because it hired so many famous aging scientists?

No. Altos Labs may have the strongest concentration of rejuvenation researchers anywhere in biotech, but the public evidence is still too early to call it the scientific leader in longevity therapeutics.

Altos launched with roughly $3 billion and recruited researchers with deep expertise in cellular reprogramming, stress resilience, regeneration and aging biology. Several of the scientific ideas surrounding the company helped establish that transient reprogramming can alter age-related cellular states without necessarily pushing cells all the way back to pluripotency.

That creates an extraordinary research environment. It does not give us much clinical evidence to score.

Altos has disclosed far less about individual therapeutic candidates, human studies and pharmacodynamic results than companies such as BioAge or Cambrian. The gap is especially striking because Altos has substantially more resources than most of the field.

We would put Altos near the top if the question were which organization could make an important discovery about cellular rejuvenation. The current question is stricter: which startups have the most credible science behind actual therapies?

Today, Altos still has to show more of that translation.

If you want more recent data on this point, please see our latest longevity biotech market report.

Could dog-longevity trials tell us more than another human aging biomarker study?

Yes. A well-controlled dog-longevity trial could teach us more about whether aging itself can be pharmacologically modified than many short human studies built around biological-age biomarkers.

Dogs age quickly enough that researchers can measure lifespan within a realistic trial period. They also develop spontaneous cancers, cardiovascular problems, cognitive decline and other diseases associated with aging while living in the same messy environments humans do.

Loyal is exploiting that opportunity directly. Its programs are being developed through the FDA Center for Veterinary Medicine, and its pivotal work is designed around longevity and healthy aging in companion dogs rather than a laboratory mouse endpoint.

The broader scientific experiment is also happening outside Loyal. The Dog Aging Project's TRIAD study is a randomized, double-masked, placebo-controlled trial testing whether rapamycin can extend lifespan and improve healthspan in pet dogs.

The results will still be canine results. We cannot assume that a treatment extending a dog's life will extend ours.

But a survival benefit across genetically diverse companion animals would be difficult to dismiss. It would give the longevity field direct mammalian lifespan evidence under ordinary living conditions, something no human biotech trial can realistically provide anytime soon.

Which aging mechanisms have the strongest science today?

Nutrient sensing and inflammatory pathways currently have the deepest combination of aging biology and human translation, while partial reprogramming offers a much bigger biological effect with far more uncertainty.

mTOR is probably the clearest example of mature geroscience. Manipulating the pathway extends lifespan across several experimental organisms, and rapamycin remains one of the most reproducible pharmacological lifespan interventions in mice. Cambrian is trying to separate mTORC1 inhibition from some of the liabilities associated with broader chronic mTOR inhibition.

AMPK belongs in roughly the same scientific neighborhood. The pathway responds to cellular energy demand and interacts with exercise physiology, glucose metabolism, mitochondrial activity and other processes that change with age. Cambrian has now added human pharmacology to that older preclinical foundation through ATX-304.

Inflammation has an even stronger bridge into human disease. Chronic inflammatory activity rises with age, and large studies outside the longevity sector have already shown that altering inflammatory pathways can change cardiovascular outcomes. BioAge is narrowing that idea to NLRP3 and testing the hypothesis prospectively.

Senescence sits one step further out. Animal experiments are extensive, but human therapeutic validation remains thin. Rubedo's early skin data make the mechanism more interesting now than it was before, although one small trial cannot validate the whole senolytic field.

Partial reprogramming has the highest ceiling. Animal studies suggest that aged cells can recover surprisingly youthful functions after their epigenetic state is altered. Yet the safety problem is fundamentally harder because reprogramming factors control cell identity and growth as well as age-related gene expression.

That leaves us with a fairly clear trade-off today. AMPK, mTOR and inflammatory biology carry less scientific drama but more translational confidence. Reprogramming could produce a much deeper form of rejuvenation if companies learn to control it safely.

Aging mechanism	Human translation today	Depth of preclinical evidence	Main scientific problem
mTOR modulation	Moderate	Very strong	Achieving chronic benefit without unwanted systemic effects
AMPK activation	Early but measurable	Strong	Showing metabolic effects translate into durable clinical benefit
NLRP3 / inflammatory aging	Strong and growing	Strong	Proving benefits extend beyond conventional anti-inflammatory treatment
Autophagy enhancement	Early	Strong	Measuring whether improved cellular cleanup changes disease outcomes
Senescent-cell targeting	Very early	Strong	Identifying which senescent cells should actually be targeted
Partial epigenetic reprogramming	Just entering humans	Strong but younger field	Safety, delivery and preserving cell identity
Transcriptional network resetting	Preclinical	Emerging	Showing broad cellular rescue survives human translation

What results could completely change the longevity biotech ranking?

The ranking could move quickly from here because several companies are approaching experiments that are much harder to explain away than another mouse study.

Life Biosciences is the clearest example. First-in-human interim ER-100 results are due on October 8, 2026. A convincing visual-function improvement accompanied by an acceptable safety profile would be the first real human evidence supporting therapeutic partial reprogramming and would immediately push Life Biosciences toward the top of this list.

BioAge has another decisive test coming through QUELL-CV. Phase 1 has already shown that BGE-102 can suppress inflammatory biology strongly. Phase 2 now has to show that the response remains clean and dose-dependent in a larger randomized population. QUELL-DME then raises the bar further by asking whether the drug improves vision.

Cambrian's next question is scale. ATX-304 produced several encouraging metabolic changes in a 23-person study. REWIRE-1 and REWIRE-2 should tell us whether those effects hold up in larger populations and whether they translate into clinically useful weight-loss, metabolic or muscle-preservation benefits.

NewLimit will face a different transition when its first reprogramming medicine enters human testing. Its preclinical platform has produced increasingly sophisticated functional evidence; human safety and target engagement will determine whether that engineering work was actually predictive.

And then there is the lifespan question. A convincing survival benefit in a large randomized companion-dog trial would give longevity biology something that even the most advanced human startup does not yet possess: direct evidence that a drug can make a diverse, naturally aging mammal live longer.

So which longevity biotech startups actually have the most credible science?

BioAge and Cambrian currently lead on the combination of aging rationale and human evidence; Life Biosciences has the strongest shot at changing the definition of what a longevity therapy can do.

BioAge takes the top spot for evidence already in hand. BGE-102 produced large, coherent inflammatory effects in Phase 1, QUELL-CV has completed enrollment, and a second Phase 2 trial is now testing an actual visual endpoint in diabetic macular edema. That is the deepest current clinical package among companies explicitly built around human aging biology.

Cambrian sits very close behind. ATX-304 has already shown human effects across liver fat, visceral fat, triglycerides, adiponectin and resting metabolism, and the program is progressing toward two Phase 2 studies. Its separate mTORC1 work gives Cambrian one of the strongest portfolios grounded in established geroscience.

Rubedo ranks next among the companies with human efficacy clues. A 46% reduction in actinic-keratosis lesions is interesting enough to take seriously, while the study remains too small and too lightly controlled to justify a stronger claim.

Life Biosciences is the wild card. ER-100 has much less human evidence today than BioAge's or Cambrian's drugs, but successful partial reprogramming would be scientifically more important. The first-in-human interim readout is therefore one of the most consequential longevity results to watch.

Among preclinical companies, NewLimit stands out for repeatedly connecting molecular rejuvenation with functional recovery and for moving a specific candidate through manufacturing toward human testing. Junevity deserves a place nearby because its foundational transcriptional-reset work is peer-reviewed, mechanistically specific and already extends from human cells into aged animals.

Retro is harder to score. RTR242 gives the company a real clinical program around autophagy, but Retro releases too little human data for us to rank it higher yet. Altos remains the opposite kind of bet: enormous scientific firepower, fascinating biology and very little public therapeutic evidence to judge.

The important change is that longevity biotech no longer has to be ranked by famous founders, giant funding rounds or record-setting mouse studies. We can increasingly rank these companies by what happens in humans.

Right now, BioAge has the best evidence. Cambrian has the strongest classic-geroscience translation. Life Biosciences is attempting the experiment with the biggest scientific upside. NewLimit and Junevity are the preclinical programs we would take most seriously.

None has proved that it can slow human aging yet. The difference today is that several finally have experiments capable of proving it wrong.

If you want more recent data on this point, please see our latest longevity biotech market report.